The collaboration will focus on enhancing surgeon capabilities, developing structured training pathways, and promoting the adoption of robotic-assisted surgery in both routine and complex procedures
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
Subscribe To Our Newsletter & Stay Updated
